대한뉴팜

The company’s newly launched non-reimbursable injectable products have successfully established a firm position in the market, becoming a key driver of new revenue growth.

In April of last year, Daehan New Pharm launched “New-DN Injection” formulated with Polydeoxyribonucleotide (commonly known as the salmon DNA ingredient). Later, in December, the company signed an exclusive sales agreement with HaspiCare Co., Ltd. to distribute the mistletoe injection “Iscador (ISCADOR).”

“New-DN Injection” is primarily used in departments such as anesthesiology and pain medicine, orthopedics, and dermatology as an adjunct therapy for pain treatment and aesthetic procedures. “Iscador,” an immune-boosting mistletoe extract used as an anticancer adjuvant, is mainly administered in convalescent hospitals and oncology clinics.

Although the non-reimbursable nutritional injection market has stagnated due to oversupply following the release of generic products, Daehan New Pharm has continued to expand and restructure its portfolio by diversifying into new therapeutic areas such as pain relief and anticancer adjuvant treatments.

In addition, in April this year, the company began exclusive domestic sales of HA fillers—“Qugel,” “Flore,” and “Cheongaan”—manufactured by Korea BNC Co., further expanding its reach into the filler market.

Among its 30 non-reimbursable injectable products, the newly introduced “New-DN Injection” “Iscador,” and HA filler lines have achieved a combined 30% share of total injectable sales within just one year of launch. As the non-reimbursable injection market continues to evolve, Daehan New Pharm plans to lead market transformation by continuously introducing differentiated and innovative new products.